Komipharm International (041960) stock
KOSDAQ · Pharmaceuticals
As of Nov 16, 3:06 PM KST
- Market cap
- KRW 606.6 billion
- As of Nov 16, 2026
- P/E
- -89.93x
- Trailing twelve months
- P/B
- 8.46x
- Latest reported equity
- P/S
- 11.52x
- Trailing twelve months
- ROE
- -9.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 606.6 billion
- As of Nov 16, 2026
- P/E
- -89.93x
- Trailing twelve months
- P/B
- 8.46x
- Latest reported equity
- P/S
- 11.52x
- Trailing twelve months
- ROE
- -9.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-89.93x
Net loss — not comparable
P/B
8.46x
P/S
11.52x
Earnings and dividend metrics▾
Earnings
EPS
-KRW 90
Earnings per share
BPS
KRW 961
Book value per share
ROE
-9.4%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at KRW 90 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 961 of net assets.
- ROE — shareholder equity shrank by 9.4% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 13, 2026 | KRW 16.7 billion | KRW 1.6 billion | KRW 500 million | +22.1% |
| Q1 2026Consolidated · Filed May 14, 2026 | KRW 11.9 billion | KRW 300 million | KRW 700 million | -17.2% |
| Q4 2025Consolidated · Filed Mar 18, 2026 | KRW 11.9 billion | -KRW 200 million | -KRW 4.3 billion | — |
| Q3 2025Consolidated · Filed Nov 14, 2025 | KRW 12.5 billion | KRW 100 million | -KRW 300 million | +13.6% |
| Q2 2025Consolidated · Filed Aug 13, 2025 | KRW 13.7 billion | KRW 1.6 billion | -KRW 3.3 billion | -28.6% |
| Q1 2025Consolidated · Filed May 14, 2025 | KRW 14.4 billion | KRW 500 million | -KRW 100 million | +11.7% |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 18, 2026 | KRW 52.5 billion | KRW 2 billion | -KRW 8 billion | — |
| FY2024Consolidated · Filed Mar 18, 2025 | KRW 58.8 billion | KRW 6.2 billion | KRW 14.7 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 5.47%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 60 million
- Previous 20-day average 7.52%
- Net short position
- 866,489 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 3,095,385 shares
- As of Nov 13, 2026 · 4.15% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 5.47% | KRW 60 million |
| Nov 12, 2026 | 0.39% | KRW 0 |
| Nov 11, 2026 | 2.58% | KRW 40 million |
| Nov 10, 2026 | 0.57% | KRW 10 million |
| Nov 9, 2026 | 4.24% | KRW 50 million |
| Nov 6, 2026 | 2.27% | KRW 40 million |
| Nov 5, 2026 | 9.62% | KRW 110 million |
| Nov 4, 2026 | 5.61% | KRW 60 million |
| Nov 3, 2026 | 12.38% | KRW 110 million |
| Nov 2, 2026 | 9.03% | KRW 140 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- [Amended] Single Sales or Supply ContractNov 4, 2026 · Supply ContractEnglish
- Report on Specified Securities Held by Executives and Major ShareholdersOct 27, 2026 · Insider Ownership ReportEnglish
- [Amended] Single Sales or Supply Contract(Korean)Sep 10, 2026 · Supply Contract
- [Amended] Single Sales or Supply Contract(Korean)Apr 8, 2026 · Supply Contract
- Results of Annual General Meeting(Korean)Mar 26, 2026 · Shareholders Meeting
- [Amended] Resolution to Convene a Shareholders Meeting(Korean)Mar 11, 2026 · Shareholders Meeting
- [Amended] Change of 30% or More in Revenue or Profit Structure (15% for Large Companies)(Korean)Mar 11, 2026 · Preliminary Earnings
- Proxy Solicitation Reference Document(Korean)Mar 11, 2026 · Proxy Solicitation
Filings with a published English version open in English; the rest link to the Korean original.
Komipharm International (041960) stock information
KOSDAQ
Komipharm International (041960) is listed on KOSDAQ. Its market capitalization is about KRW 606.6 billion. On trailing-twelve-month earnings the P/E ratio is -89.93, and the P/B ratio is 8.46. Return on equity is -9.4%. These figures are computed in-house from official filings and are reference information only.
Komipharm International — frequently asked questions
- What is the P/E ratio of Komipharm International (041960)?
- On a trailing-twelve-month basis, 041960 trades at a P/E ratio of -89.93. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Komipharm International?
- 041960 has a market capitalization of about KRW 606.6 billion. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.